生命科学资讯

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

A protein model designed for space could expand pharma’s definition of ‘druggability’

New FDA guidance that’s a ‘huge deal’ for clinical trials

In a tough market, biotechs can be their own worst enemy

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Bayer sets the stage for a pharma comeback

The most valuable up-and-coming GLP-1s

Big Pharma CEOs set sights on massive growth in years to come

Why TrumpRx is stumbling before it gets off the ground

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

Mirum doubles down on diversified rare disease strategy

AI regulation lags despite entering higher-risk patient care

Pharma’s outlook in 2026: Smoother sailing ahead?

How Big Pharma is navigating a $300 billion patent cliff

Politicization runs deeper than ever at FDA, risking long-term impacts

Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential

Has Novavax cracked the code for survival in the vaccine arena?

A potential gene therapy for heart failure is an approach decades in the making

Biopharma layoffs surged last year, but 2026 is a chance to turn the page

Big Pharma shops Chinese biotechs to stock GLP-1 pipelines